<code id='DB00768DEB'></code><style id='DB00768DEB'></style>
    • <acronym id='DB00768DEB'></acronym>
      <center id='DB00768DEB'><center id='DB00768DEB'><tfoot id='DB00768DEB'></tfoot></center><abbr id='DB00768DEB'><dir id='DB00768DEB'><tfoot id='DB00768DEB'></tfoot><noframes id='DB00768DEB'>

    • <optgroup id='DB00768DEB'><strike id='DB00768DEB'><sup id='DB00768DEB'></sup></strike><code id='DB00768DEB'></code></optgroup>
        1. <b id='DB00768DEB'><label id='DB00768DEB'><select id='DB00768DEB'><dt id='DB00768DEB'><span id='DB00768DEB'></span></dt></select></label></b><u id='DB00768DEB'></u>
          <i id='DB00768DEB'><strike id='DB00768DEB'><tt id='DB00768DEB'><pre id='DB00768DEB'></pre></tt></strike></i>

          focus

          focus

          author:Wikipedia    Page View:747
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand. Adobe

          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

          advertisement

          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          FDA approves world's first CRISPR
          FDA approves world's first CRISPR

          ChristineKao/STATTheFoodandDrugAdministrationonFridayapprovedtheworld’sfirstmedicinebasedonCRISPRgen

          read more
          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

          AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

          read more

          Leukemia patients are helped by Syndax's new type of therapy

          AdobeSANDIEGO—OneofthetoughestsubtypesofacuteleukemiainvolvesageneticalterationintheKMT2Agene.Manyca